At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Nov 8, 2026 at 16:35 ET
Mineralys Therapeutics presented long-term data from the Transform-HTN open-label extension trial of lorundrostat at AHA 2026, showing a sustained 17.8 mmHg reduction in systolic blood pressure at 48 weeks with 56% of participants achieving blood pressure below 130 mmHg. The FDA review of lorundrostat is ongoing with a PDUFA target date of December 22, 2026, and the data strengthens the safety and efficacy profile ahead of the decision.
- Lorundrostat demonstrated a 17.8 mmHg reduction in AOSBP from Launch-HTN baseline to Week 48 (p<0.0001)
- 56% of participants achieved AOSBP below 130 mmHg at Week 48
- 92% of participants completed 48 weeks of follow-up; serious adverse events in 4.3% (0.3% treatment-related)
- FDA PDUFA target date for lorundrostat is December 22, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access